How to Pick the Best Cancer Proteins for a Vaccine
This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components.
Patent Number
US 20250244311
Status
Active
Filing Date
October 18, 2024
Grant Date
—
Expiration
October 18, 2044
Claims
22
Assignee
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG -UNIVERSITÄT MAINZ
Inventors
Ugur Sahin, Mathias Vormehr, Martin Löwer, Barbara Schrörs, Sebastian Boegel
Citations
0 forward · 0 backward
What it covers
The patent describes a method for making vaccines, especially for personalized cancer treatment. It involves identifying specific proteins or protein pieces from diseased cells that would be useful for immunotherapy. This identification step, as per claim 20, checks for one or more of three things: (a) if the body already has antibodies against these proteins, (b) if these proteins bind to a cell structure called F-actin, or (c) if they bind to RNA. If any of these conditions are met, it suggests the protein or its genetic code is a good candidate for a vaccine. The method then involves manufacturing a vaccine containing these selected proteins or their genetic instructions. For example, if a patient's tumor cells express a unique protein that the patient's immune system has already started to make antibodies against, that protein would be selected for inclusion in a personalized vaccine (claim 20a).
What it doesn't cover
- —Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.
- —Does not cover methods for making vaccines that do not involve determining these specific binding or response properties of the proteins.
- —Does not cover vaccines made from proteins that are not expressed by diseased cells, as specified in claim 20.
- —Does not cover general vaccine manufacturing processes that do not incorporate this specific protein selection methodology.
- —Does not cover immunotherapy approaches that do not involve a vaccine, such as direct antibody infusions or CAR-T cell therapy.
The clever bit
The novelty lies in using specific indicators—an existing antibody response, or the binding of a protein to F-actin or RNA—as a way to predict which tumor proteins will be most effective at triggering an immune response when used in a vaccine. This moves beyond simply identifying tumor-specific proteins to selecting those with a higher likelihood of being "useful for immunotherapy" (claim 20).
Why it matters
This patent is significant for the field of personalized cancer immunotherapy. By providing a specific method to identify highly immunogenic (immune-stimulating) proteins from a patient's own tumor, it aims to improve the effectiveness of cancer vaccines. This approach could lead to vaccines that are precisely tailored to an individual's unique cancer, potentially reducing side effects and increasing treatment success compared to more general cancer therapies.
Real-world examples
- 1.Personalized mRNA cancer vaccines
- 2.Neoantigen-based cancer immunotherapies
- 3.Vaccines for solid tumors
- 4.Individualized cancer treatment plans
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20250244311 · 2026